In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship

Clinical Cancer Research

Volumn 9, Issue 1 I, 2003, Pages 327-337

  Mendel, Dirk B ^a   Douglas Laird, A ^a   Xin, Xiaohua ^a   Louie, Sharianne G ^a   Christensen, James G ^a   Li, Guangmin ^a   Schreck, Randall E ^a   Abrams, Tinya J ^a   Ngai, Theresa J ^a   Lee, Leslie B ^a   Murray, Lesley J ^a   Carver, Jeremy ^a   Chan, Emily ^a   Moss, Katherine G ^a   Haznedar, Joshua Ö ^a   Sukbuntherng, Juthamas ^a   Blake, Robert A ^a   Sun, Li ^a   Tang, Cho ^a   Miller, Todd ^a   Shirazian, Sheri ^a   McMahon, Gerald ^a   Cherrington, Julie M ^a   more..

^a SUGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEFITINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER CELL; COMPETITIVE INHIBITION; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LIGAND BINDING; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; ENZYME INHIBITORS; FEMALE; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; KINETICS; MICE; MICE, NUDE; MODELS, CHEMICAL; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PYRROLES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 12244301581     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell, 103: 211-225, 2000.
2. Hanahan, D., and Weinberg, R. A. The hallmarks of cancer. Cell, 100: 57-70, 2000.
3. Cherrington, J. M., Strawn, L. M., and Shawver, L. K. New paradigms for the treatment of cancer; the role of anti-angiogenesis agents. In: G. Klein and G. F. Vande Woude (eds.), Advances in Cancer Res., I edition, Vol. 79, pp. 1-38. San Diego, CA: Academic Press, 2000.
4. Heinrich, M. C., Blanke, C. D., Druker, B. J., and Corless, C. L. Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies. J. Clin. Oncol., 20: 1692-1703, 2002.
5. Shimizu, A., O'Brien, K. P., Sjoblom, T., Pietras, K., Buchdunger, E., Collins, V. P., Heldin, C-H., Dumanski, J. P., and Ostman, A. The dermatofibrosarcoma protuberans-associated collagen type Iα1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res., 59: 3719-3723, 1999.
6. Gilliland, D. G. and Griffin, J. D. Role of FLT3 in leukemia. Curr. Opin. Hematol., 9: 274-281, 2002.
7. Reilly, J. T. Class III receptor tyrosine kinases: Role in leukaemo-genesis. Br. J. Haematol., 116: 744-757, 2002.
8. Ferrara, N. Molecular and biological properties of vascular endothelial growth factor. J. Mol. Med., 77: 527-543, 1999.
9. Sundberg, C., Ljungstrom, M., Lindmark, G., Gerdin, B., and Rubin, K. Microvascular pericytes express platelet-derived growth factor-beta receptors in human healing wounds and colorectal adenocarcinoma. American Journal of Pathology, 143: 1377-1388, 1993.
10. Plate, K. H., Breier, G., Weich, H. A., and Risau, W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature, 359: 845-848, 1992.
11. Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E. C., Lu, N., Selig, M., Nielsen, G., Taksir, T., Jain, R. K., and Seed, B. Tumor induction of VEGF promoter activity in stromal cells. Cell, 94: 715-725, 1998.
12. Laird, A. D., Christensen, J. G., Li, G., Carver, J., Smith, K., Xin, X., Moss, K. G., Louie, S. G., Mendel, D. B., and Cherrington, J. M. SU6668 inhibits Flk-1/KDR and PDGRFb in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J., 16: 681-690, 2002.
13. Elsayed, Y. A., and Suasville, E. A. Selected novel anticancer treatments targeting cells signaling proteins. Oncologist, 6: 517-537, 2001.
14. Arteaga, C. L., and Johnson, D. H. Tyrosine kinase inhibitors-ZD1839. Curr. Opin. Oncol., 13: 491-498, 2001.
15. Laird, A. D., Vajkoczy, P., Shawver, L. K., Thurnher, A., Liang, C., Mohammadi, M., Schlessinger, J., Ullrich, A., Hubbard, S. R., Blake, R. A., Fong, T. A. T., Strawn, L. M., Sun, L., Tang, C., Hawtin, R., Tang, F., Shenoy, N., Hirth, K. P., McMahon, G., and Cherrington, J. M. SU6668, a broad spectrum angiogenesis inhibitor, exhibits potent anti-tumor activity in xenograft models, including regression of established tumors. Cancer Res., 60: 4152-4160, 2000.
16. Fong, T. A., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T. J., Kim, Y. H., Schreck, R., Wang, X., Risau, W., Ullrich, A., Hirth, K. P., and McMahon, G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res., 59: 99-106, 1999.
17. Mendel, D. B., Schreck, R. E., West, D. C., Li, G., Strawn, L. S., Tanciongco, S. S., Vasile, S., Shawver, L., K., and Cherrignton, J. M. The angiogenesis inhibitor SU5416 has long lasting effects on VEGF receptor phosphorylation and function. Clin. Cancer Res., 6: 4848-4858, 2000.
18. Smolich, B. D., Yuen, H. A., West, K. A., Giles, F. J., Albitar, M., and Cherrington, J. M. The anti-angiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (KIT) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood, 97: 1413-1421, 2001.
19. Mendel, D. B., Laird, D. A., Smolich, B., Blake, R. A., Liang, C., Hannah, A. L., Shaheen, R. M., Lee, M. E., Shawver, L. K., and Cherrington, J. M. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anti-Cancer Drug Des., 15: 29-41, 2000.
20. Christensen, J. G., Schreck, R. E., Chan, E., Wang, X., Yang, C., Liu, L., Cui, J., Sun, L., Wei, J., Cherrington, J. M., and Mendel, D. B. High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo. Clin. Cancer Res., 7: 4230-4238, 2001.
21. Miles, A. A., and Miles, E. M. Vascular reactions to histamine, histamine-liberator and leukotaxine in the skin of guinea pigs. J. Physiol., 118: 228-257, 1952.
22. O'Farrell, A-M., Abrams, T. J., Yuen, H. A., Ngai, T. J., Louie, S. G., Yee, W. H., Wong, L. M., Hong, W., Lee, L. B., Town, A., Smolich, B. D., Manning, W. C., Murray, L. J., Heinrich, M. C., and Cherrington, J. M. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood, in press.
23. Rice, B. W., Cable, M. D., and Nelson, M. B. In vivo imaging of light-emitting probes. J. Biomed. Opt., 6: 432-440, 2001.
24. Mauro, M. J., O'Dwyer, M., Heinrich, M. C., and Druker, B. J. STI-571: A paradigm of new agents for cancer therapeutics. J. Clin. Oncol., 20: 325-334, 2002.
25. Druker, B. J., and Lydon, N. B. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Investig., 105: 3-7, 2000.
26. Albanell, J., Rojo, F., Averbuch, S., Feyereislova, A., Mascaro, J. M., Herbst, R., LoRusso, P., Rischin, D., Sualeda, S., Gee, J., Nicholson, R. I., and Baselga, J. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition. J. Clin. Oncol., 20: 110-124, 2002.
27. Mangold, U., Dax, C. I., Saar, K., Schwab, W., Kirschbaum, B., and Müllner, S. Identification and characterization of potential new therapeutic targets in inflammatory and autoimmune diseases. Eur. J. Biochem., 266: 1184-1191, 1999.